Army Nears Crucial Brain Health Testing Milestone - U.S. Department of War (.gov)

RENTON, Wash. – The Seattle Seahawks, in partnership with Virginia Mason Franciscan Health (VMFH), the team's Official Medical Services Provider, today announced cancer awareness activities to promote early detection through the NFL's Crucial Catch: Intercept Cancer initiative. The Seahawks will host the team's annual Crucial Catch game on October 11 vs. the San Francisco 49ers. In celebration of the campaign, representatives from the Seahawks and VMFH held the annual ceremonial raising of the Crucial Catch flag at Lumen Field. "At Virginia Mason Franciscan Health, we are honored to stand with the Seattle Seahawks and team up to support the NFL's Crucial Catch initiative," said Dr. Joseph Rosales, Executive Medical Director of Cancer Services at Virginia Mason Franciscan Health (VMFH). "This campaign is a reminder that when it comes to health, we are stronger together. By offering on-site screenings at the Ticketmaster Tailgate, we want to provide our community with helpful, proactive tools to better understand their health.

Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.

The new treatment kills off a sub-group of fat cells. (Jian Fan/iStockphoto/Getty Images) Early clinical trials into a new fat reduction treatment have reported promising results, and the treatment takes a more unusual approach: Rather than shrinking fat cells, as most weight loss strategies do, it safely and naturally kills them off. The drug here is CBL-514, which is administered via injection. As well as proving effective at reducing subcutaneous fat (just below the skin), there's evidence it can also reduce visceral fat (stored deeper around the organs). According to the team behind the trials, CBL-514 and its unconventional strategy have the potential to reduce fat in key areas of the body – with further benefits that come with weight loss likely to follow. "We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss," says endocrinologist Timothy Garvey, from the University of Alabama at Birmingham, who headed up the trial.